Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria
Auto-generated profile, based on publicly available information
Ella Grilz
Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna , Waehringer Guertel 18-20, Vienna 1090, Austria
Summary: Prior studies indicate that neutrophil extracellular traps (NETs) are associated with arterial thromboembolism (ATE) and mortality. We investigated the association between NET formation biomarkers (citrullinated histone H3 [H3Cit], cell‐free DNA [cfDNA], and nucleosomes) and the risk of ATE and all‐cause mortality in patients with cancer. In this prospective cohort study, H3Cit, cfDNA and nucleosome levels were determined at study inclusion, and patients with newly diagnosed cancer or progressive disease after remission were followed for 2 years for ATE and death. Nine‐hundred and fifty‐seven patients were included. The subdistribution hazard ratios for ATE of H3Cit, cfDNA and nucleosomes were 1·0 per 100 ng/ml increase (95% confidence interval [95% CI]: 0·7–1·4, P = 0·949), 1·0 per 100 ng/ml (0·9–1·2, P = 0·494) increase and 1·1 per 1‐unit increase (1·0–1·2, P = 0·233), respectively. Three‐hundred and seventy‐eight (39·5%) patients died. The hazard ratio (HR) for mortality of H3Cit and cfDNA per 100 ng/ml increase was 1·1 (1·0–1·1, P < 0·001) and 1·1 (1·0–1·1, P < 0·001), respectively. The HR for mortality of nucleosome levels per 1‐unit increase was 1·0 (1·0–1·1, P = 0·233). H3Cit, cfDNA and nucleosome levels were not associated with the risk of ATE in patients with cancer. Elevated H3Cit and cfDNA levels were associated with higher mortality in patients with cancer.
An interrelation between cancer and thrombosis is known, but population-based studies on the risk of both arterial thromboembolism (ATE) and venous thromboembolism (VTE) have not been performed. International Classification of Disease 10th Revision (ICD-10) diagnosis codes of all publicly insured persons in Austria (0–90 years) were extracted from the Austrian Association of Social Security Providers dataset covering the years 2006–07 (n = 8 306 244). Patients with a history of cancer or active cancer were defined as having at least one ICD-10 ‘C’ diagnosis code, and patients with ATE and/or VTE as having at least one of I21/I24 (myocardial infarction), I63/I64 (stroke), I74 (arterial embolism), and I26/I80/I82 (venous thromboembolism) diagnosis code. Among 158 675 people with cancer, 8559 (5.4%) had an ATE diagnosis code and 7244 (4.6%) a VTE diagnosis code. In contrast, among 8 147 569 people without cancer, 69 381 (0.9%) had an ATE diagnosis code and 29 307 (0.4%) a VTE diagnosis code. This corresponds to age-stratified random-effects relative risks (RR) of 6.88 [95% confidence interval (CI) 4.81–9.84] for ATE and 14.91 (95% CI 8.90–24.95) for VTE. ATE proportion was highest in patients with urinary tract malignancies (RR: 7.16 [6.74–7.61]) and lowest in patients with endocrine cancer (RR: 2.49 [2.00–3.10]). The corresponding VTE proportion was highest in cancer of the mesothelium/soft tissue (RR: 19.35 [17.44–21.47]) and lowest in oropharyngeal cancer (RR: 6.62 [5.61–7.81]). The RR of both ATE and VTE are significantly higher in persons with cancer. Our population-level meta-data indicate a strong association between cancer, ATE and VTE, and support the concept of shared risk factors and pathobiology between these diseases. Relative risk of ATE and VTE in persons with a cancer diagnosis code versus persons without a cancer diagnosis code. Relative risk of ATE and VTE in persons with a cancer diagnosis code versus persons without a cancer diagnosis code